[Effect of increasing the infliximab dose in rheumatoid arthritis].
Schmalzing
M
M
Abt. Innere Medizin II, Medizinische Universitätsklinik, Otfried-Müller-Strasse 10, Tübingen, Germany. marc.schmalzing@med.uni-tuebingen.de
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000069285:Infliximab; D008727:Methotrexate / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab; D008727:Methotrexate